MS-Leaders Home


Click here to Register



Remember Me \| Forgot Password \| Send to a Colleague

Clinical Dialogue & eCase Challenge

Ask The Experts

MS-Leaders.org™ is an online educational resource for MS treating clinicians designed to provide cutting edge information and resources to help support patient care. MS-Leaders.org provides a variety of engaging and clinically relevant educational platforms to deliver a breadth of content to meet the needs of busy clinicians:

Clinical Dialogues and eCase Challenges: Clinical Dialogues are video-based moderated discussions featuring leading MS experts. Clinical Dialogues are accompanied by an interactive eCase Challenge, which presents challenging case scenarios and supports the application of the education delivered in the Clinical Dialogue program into clinical practice. Following each case, a video commentary provides key clinical pearls that summarize the most important aspects of the case.

Ask the Expert: Ask the Expert provides MS-Leaders.org registrants with the opportunity to present their own clinical challenges to leading MS experts, and to review a growing library of archived questions and answers. Responses to questions are sent directly to the registrant posing the question, thus providing a unique opportunity for MS treating clinicians to readily access leading MS experts.

We encourage you to register with MS-Leaders.org today and to take advantage of the many resources that this unique online educational site offers.

MS-Leaders.org™ is a trademark of Medical Logix, LLC.

[X] Close

About MS-Leaders

Clinical Dialogues and eCase Challenges: Clinical Dialogues are video-based moderated discussions featuring leading MS experts. Clinical Dialogues are accompanied by an interactive eCase Challenge, which presents challenging case scenarios and supports the application of the education delivered in the Clinical Dialogue program into clinical practice. Following each case, a video commentary provides key clinical pearls that summarize the most important aspects of the case.
Ask the Expert: Ask the Expert provides MS-Leaders.org registrants with the opportunity to present their own clinical challenges to leading MS experts, and to review a growing library of archived questions and answers. Responses to questions are sent directly to the registrant posing the question, thus providing a unique opportunity for MS treating clinicians to readily access leading MS experts.

We encourage you to register with MS-Leaders.org today and to take advantage of the many resources that this unique online educational site offers.

MS-Leaders.org™ is a trademark of Medical Logix, LLC.

As coronavirus disease 19 (COVID-19) has become a worldwide issue, being declared a pandemic by the World Health Organization, it affects many aspects of healthcare. Specifically, many patients with multiple sclerosis (MS) take medications that alter or suppress their immune system. Rightly, they and their treatment team are concerned about the safest, but also most effective treatment strategy that considers both MS and the risk of COVID-19.

This balance is not simple. Those with comorbidities such as poor mobility and poor lung function are at increased risk of worse COVID-19 outcomes. The impact of immunosuppression is not clearly understood. MS itself is surprisingly common, with up to one million adults in the US diagnosed with this condition. Many of these patients take disease-modifying therapies (DMTs) to treat their MS and mitigate disease progression and prevent symptoms such as muscle weakness, poor coordination, impaired vision, etc. For many years, the treatment paradigm has been to “treat early and never stop,” but in the light of these recent world changes, this paradigm is much less clear.

Physicians caring for patients with MS during this period of COVID-19 risk require educational programs to stay informed of the proper use of DMTs and relevant guidelines to best treat their patients and reduce breakthroughs, while still mitigating the risk of COVID-19.

The University of Texas Southwestern Medical Center designates this enduring material for a maximum of 1.0 AMA PRA Category Credits^TM

Click here to view this program